Halozyme Therapeutics (HALO) 16.86 $HALO
Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO
PR Newswire - Mon Apr 20, 7:15AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today shared highlights of new data it presented at the American Association for Cancer Research (AACR) annual meeting. Halozyme also announced plans to present interim results of its randomized Phase 2 study in pancreatic cancer, Study 202, next month at the annual meeting of the American Society of Clinical Oncology (ASCO).
HALO: 16.86 (-0.08)
Updates on Biotech Stocks -- Gilead Sciences, Arena Pharma, ACADIA Pharma, Halozyme Therapeutics, and Anthera Pharma
PR Newswire - Tue Apr 14, 7:40AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ACAD: 38.36 (-0.54), HALO: 16.86 (-0.08), GILD: 103.69 (-1.52), ANTH: 5.20 (+0.31), ARNA: 4.49 (+0.05)
Halozyme Therapeutics Appoints Harry J. Leonhardt, Esq. As Senior Vice President, General Counsel And Chief Compliance Officer
PR Newswire - Mon Apr 13, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of Harry J. Leonhardt, Esq., as senior vice president, general counsel and chief compliance officer, reporting to Dr. Helen Torley, president and chief executive officer.
HALO: 16.86 (-0.08)
Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 401.71 (-28.57), SPHS: 0.80 (-0.03), ADMS: 17.70 (-0.03), TKMR: 18.75 (-0.25), CBYL: 7.45 (-0.11), HPTX: 45.97 (-0.11), QURE: 26.09 (-0.28), SHPG: 255.11 (-0.26), SRPT: 13.42 (-0.24), HZNP: 31.75 (+0.97), GALE: 1.45 (+0.02), JUNO: 56.66 (-1.06), ABBV: 66.07 (+1.82), CBMG: 29.51 (-1.85), ARNA: 4.49 (+0.05), EXEL: 3.08 (-0.02), ADXS: 23.34 (-0.27), PTLA: 38.51 (-0.85), BMY: 65.80 (-0.20), OCUL: 25.36 (-1.12), NVO: 56.65 (+0.44), DVA: 83.91 (+0.50), HALO: 16.86 (-0.08), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), ALXN: 180.08 (-4.50), NVS: 104.28 (-1.22)
Halozyme to Advance PEGPH20 Following FDA Meet - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 3:20PM CDT
Halozyme (HALO) announced that it will advance PEGPH20 into a phase III study following its meeting with the FDA.
CYTK: 7.25 (-0.18), HALO: 16.86 (-0.08), CBM: 42.97 (+0.37), AMGN: 167.91 (-1.26)
Halozyme moves to Phase 3 with PEGPH20 in pancreatic cancer
Seeking Alpha - at Seeking Alpha - Wed Apr 08, 10:30AM CDT
HALO: 16.86 (-0.08)
Halozyme Provides Update Following Type B FDA Meeting
PR Newswire - Wed Apr 08, 8:15AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced it plans to proceed with a Phase 3 clinical study (Study 301) of its investigational new drug PEGPH20 in patients with metastatic pancreatic cancer, using a design allowing for potential marketing application based on either progression free survival (PFS) or overall survival.
HALO: 16.86 (-0.08)
Individual Investor Portfolio: Select Sectors And Companies Continue To Beat Market Indices And Peer Groups
James Sands - at Seeking Alpha - Tue Mar 31, 8:40PM CDT
PCYC: 256.59 (-0.51), FB: 81.53 (-0.88), LJPC: 22.95 (-1.39), SAFM: 76.06 (-0.23), ICE: 223.39 (-1.80), ILMN: 189.59 (-3.01), HP: 74.42 (-0.91), PCLN: 1,233.09 (+11.99), WWAV: 45.60 (-0.08), SQNM: 4.52 (-0.10), ACAD: 38.36 (-0.54), HALO: 16.86 (-0.08), GILD: 103.69 (-1.52), TRN: 28.70 (-4.66), QCOM: 68.24 (-0.10), FFIV: 123.18 (+0.78), MBLY: 47.62 (+0.01), UNP: 107.51 (-0.61), MA: 90.72 (-0.16), IPGP: 94.50 (-2.04)
Halozyme Therapeutics Appoints James Mazzola To Lead Corporate Communications, Investor Relations
PR Newswire - Mon Mar 23, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of James S. Mazzola as vice president, Corporate Communications and Investor Relations, reporting to President and CEO Dr. Helen Torley.
HALO: 16.86 (-0.08)
Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 20, 7:00PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HALO: 16.86 (-0.08), VCYT: 9.63 (+0.40), VTL: 29.37 (+0.19), ZSAN: 8.80 (-0.10), FCCY: 11.68 (+0.22)
64.6% Return Seen to Date on SmarTrend Halozyme Therapeutics Call (HALO)
Comtex SmarTrend(R) - Thu Mar 19, 9:20AM CDT
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on January 5th, 2015 at $9.95. In approximately 2 months, Halozyme Therapeutics has returned 64.62% as of today's recent price of $16.38.
HALO: 16.86 (-0.08)
Akamai Technologies Is A Terrific Connectivity Play - Cramer's Lightning Round (3/18/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Mar 19, 4:35AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, March 18. Bullish Calls: Akamai Technologies (NASDAQ: AKAM ): "This is a content delivery system, and I think it's terrific. We keep...
AR: 42.56 (+0.26), ZIOP: 10.81 (-0.39), HALO: 16.86 (-0.08), DRNA: 24.18 (-0.25), AKAM: 75.74 (-0.53), JUNO: 56.66 (-1.06), LBIO: 12.34 (-0.08), FIVE: 36.04 (+0.10), ROST: 104.38 (-0.13)
Matthew Posard Joins Trovagene's Executive Management Team as Chief Commercial Officer
PR Newswire - Wed Mar 18, 7:31AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Matthew L. Posard has joined the Company as executive vice president & chief commercial officer. Mr. Posard has more than 20 years of experience identifying, directing and successfully commercializing innovative technologies in the molecular diagnostic and life science fields. Most recently, he led the new and emerging market opportunities business at Illumina, Inc. (NASDAQ: ILMN).
HALO: 16.86 (-0.08), TROV: 8.80 (-0.13), ILMN: 189.59 (-3.01)
Halozyme Therapeutics Has Returned 54.9% Since SmarTrend Recommendation (HALO)
Comtex SmarTrend(R) - Wed Mar 11, 4:53PM CDT
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on January 5th, 2015 at $9.95. In approximately 2 months, Halozyme Therapeutics has returned 54.87% as of today's recent price of $15.41.
HALO: 16.86 (-0.08)
Biotech Equities Technical Updates -- Gilead Sciences, Arena Pharma, ACADIA Pharma, Halozyme Therapeutics, and Juno Therapeutics
PR Newswire - Wed Mar 11, 8:05AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ACAD: 38.36 (-0.54), HALO: 16.86 (-0.08), GILD: 103.69 (-1.52), JUNO: 56.66 (-1.06), ARNA: 4.49 (+0.05)
Clinical trial planned to assess Halozyme's Enhanze in subcutaneous version of cancer drug
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 12:23PM CDT
JNJ: 101.08 (+0.62), HALO: 16.86 (-0.08)
Insider Trading Alert - GCAP, HALO And ALIM Traded By Insiders
at The Street - Tue Mar 10, 12:16PM CDT
Stocks with insider trader activity include GCAP, HALO and ALIM
HALO: 16.86 (-0.08), ALIM: 4.94 (-0.07), GCAP: 9.81 (-0.06)
Halozyme Therapeutics Reports Selection Of First Product Candidate Under Janssen Collaboration
PR Newswire - Tue Mar 10, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported today that Genmab A/S announced plans for a Phase 1 clinical trial of a subcutaneous formulation of the anti-CD38 antibody daratumumab using the ENHANZE(TM) technology. In December 2014, Janssen Biotech, Inc. (Janssen) entered into an agreement with Halozyme Therapeutics for the purpose of developing and commercializing products combining proprietary Janssen compounds with Halozyme's ENHANZE technology. This agreement has the potential to lead to the development of a subcutaneous formulation of daratumumab. Daratumumab is being developed under a collaboration between Janssen and Genmab A/S since August 2012 when Genmab granted Janssen an exclusive worldwide license to develop, manufacture, and commercialize daratumumab.
HALO: 16.86 (-0.08)
Halozyme Q4 Loss Narrower-than-Expected, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 9:33AM CST
Halozyme (HALO) reports narrower year over year loss in its fourth quarter; Gives 2015 view.
JNJ: 101.08 (+0.62), HALO: 16.86 (-0.08), CBM: 42.97 (+0.37), BAX: 71.14 (-0.37)
Halozyme Therapeutics ups revenues 143% in Q4
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 9:06AM CST
HALO: 16.86 (-0.08)
Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO
PR Newswire - Mon Apr 20, 7:15AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today shared highlights of new data it presented at the American Association for Cancer Research (AACR) annual meeting. Halozyme also announced plans to present interim results of its randomized Phase 2 study in pancreatic cancer, Study 202, next month at the annual meeting of the American Society of Clinical Oncology (ASCO).
HALO: 16.86 (-0.08)
Updates on Biotech Stocks -- Gilead Sciences, Arena Pharma, ACADIA Pharma, Halozyme Therapeutics, and Anthera Pharma
PR Newswire - Tue Apr 14, 7:40AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ACAD: 38.36 (-0.54), HALO: 16.86 (-0.08), GILD: 103.69 (-1.52), ANTH: 5.20 (+0.31), ARNA: 4.49 (+0.05)
Halozyme Therapeutics Appoints Harry J. Leonhardt, Esq. As Senior Vice President, General Counsel And Chief Compliance Officer
PR Newswire - Mon Apr 13, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of Harry J. Leonhardt, Esq., as senior vice president, general counsel and chief compliance officer, reporting to Dr. Helen Torley, president and chief executive officer.
HALO: 16.86 (-0.08)
Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 401.71 (-28.57), SPHS: 0.80 (-0.03), ADMS: 17.70 (-0.03), TKMR: 18.75 (-0.25), CBYL: 7.45 (-0.11), HPTX: 45.97 (-0.11), QURE: 26.09 (-0.28), SHPG: 255.11 (-0.26), SRPT: 13.42 (-0.24), HZNP: 31.75 (+0.97), GALE: 1.45 (+0.02), JUNO: 56.66 (-1.06), ABBV: 66.07 (+1.82), CBMG: 29.51 (-1.85), ARNA: 4.49 (+0.05), EXEL: 3.08 (-0.02), ADXS: 23.34 (-0.27), PTLA: 38.51 (-0.85), BMY: 65.80 (-0.20), OCUL: 25.36 (-1.12), NVO: 56.65 (+0.44), DVA: 83.91 (+0.50), HALO: 16.86 (-0.08), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), ALXN: 180.08 (-4.50), NVS: 104.28 (-1.22)
Halozyme to Advance PEGPH20 Following FDA Meet - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 3:20PM CDT
Halozyme (HALO) announced that it will advance PEGPH20 into a phase III study following its meeting with the FDA.
CYTK: 7.25 (-0.18), HALO: 16.86 (-0.08), CBM: 42.97 (+0.37), AMGN: 167.91 (-1.26)
Halozyme moves to Phase 3 with PEGPH20 in pancreatic cancer
Seeking Alpha - at Seeking Alpha - Wed Apr 08, 10:30AM CDT
HALO: 16.86 (-0.08)
Halozyme Provides Update Following Type B FDA Meeting
PR Newswire - Wed Apr 08, 8:15AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced it plans to proceed with a Phase 3 clinical study (Study 301) of its investigational new drug PEGPH20 in patients with metastatic pancreatic cancer, using a design allowing for potential marketing application based on either progression free survival (PFS) or overall survival.
HALO: 16.86 (-0.08)
Individual Investor Portfolio: Select Sectors And Companies Continue To Beat Market Indices And Peer Groups
James Sands - at Seeking Alpha - Tue Mar 31, 8:40PM CDT
PCYC: 256.59 (-0.51), FB: 81.53 (-0.88), LJPC: 22.95 (-1.39), SAFM: 76.06 (-0.23), ICE: 223.39 (-1.80), ILMN: 189.59 (-3.01), HP: 74.42 (-0.91), PCLN: 1,233.09 (+11.99), WWAV: 45.60 (-0.08), SQNM: 4.52 (-0.10), ACAD: 38.36 (-0.54), HALO: 16.86 (-0.08), GILD: 103.69 (-1.52), TRN: 28.70 (-4.66), QCOM: 68.24 (-0.10), FFIV: 123.18 (+0.78), MBLY: 47.62 (+0.01), UNP: 107.51 (-0.61), MA: 90.72 (-0.16), IPGP: 94.50 (-2.04)
Halozyme Therapeutics Appoints James Mazzola To Lead Corporate Communications, Investor Relations
PR Newswire - Mon Mar 23, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of James S. Mazzola as vice president, Corporate Communications and Investor Relations, reporting to President and CEO Dr. Helen Torley.
HALO: 16.86 (-0.08)
Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 20, 7:00PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HALO: 16.86 (-0.08), VCYT: 9.63 (+0.40), VTL: 29.37 (+0.19), ZSAN: 8.80 (-0.10), FCCY: 11.68 (+0.22)
64.6% Return Seen to Date on SmarTrend Halozyme Therapeutics Call (HALO)
Comtex SmarTrend(R) - Thu Mar 19, 9:20AM CDT
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on January 5th, 2015 at $9.95. In approximately 2 months, Halozyme Therapeutics has returned 64.62% as of today's recent price of $16.38.
HALO: 16.86 (-0.08)
Akamai Technologies Is A Terrific Connectivity Play - Cramer's Lightning Round (3/18/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Mar 19, 4:35AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, March 18. Bullish Calls: Akamai Technologies (NASDAQ: AKAM ): "This is a content delivery system, and I think it's terrific. We keep...
AR: 42.56 (+0.26), ZIOP: 10.81 (-0.39), HALO: 16.86 (-0.08), DRNA: 24.18 (-0.25), AKAM: 75.74 (-0.53), JUNO: 56.66 (-1.06), LBIO: 12.34 (-0.08), FIVE: 36.04 (+0.10), ROST: 104.38 (-0.13)
Matthew Posard Joins Trovagene's Executive Management Team as Chief Commercial Officer
PR Newswire - Wed Mar 18, 7:31AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Matthew L. Posard has joined the Company as executive vice president & chief commercial officer. Mr. Posard has more than 20 years of experience identifying, directing and successfully commercializing innovative technologies in the molecular diagnostic and life science fields. Most recently, he led the new and emerging market opportunities business at Illumina, Inc. (NASDAQ: ILMN).
HALO: 16.86 (-0.08), TROV: 8.80 (-0.13), ILMN: 189.59 (-3.01)
Halozyme Therapeutics Has Returned 54.9% Since SmarTrend Recommendation (HALO)
Comtex SmarTrend(R) - Wed Mar 11, 4:53PM CDT
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on January 5th, 2015 at $9.95. In approximately 2 months, Halozyme Therapeutics has returned 54.87% as of today's recent price of $15.41.
HALO: 16.86 (-0.08)
Biotech Equities Technical Updates -- Gilead Sciences, Arena Pharma, ACADIA Pharma, Halozyme Therapeutics, and Juno Therapeutics
PR Newswire - Wed Mar 11, 8:05AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ACAD: 38.36 (-0.54), HALO: 16.86 (-0.08), GILD: 103.69 (-1.52), JUNO: 56.66 (-1.06), ARNA: 4.49 (+0.05)
Clinical trial planned to assess Halozyme's Enhanze in subcutaneous version of cancer drug
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 12:23PM CDT
JNJ: 101.08 (+0.62), HALO: 16.86 (-0.08)
Insider Trading Alert - GCAP, HALO And ALIM Traded By Insiders
at The Street - Tue Mar 10, 12:16PM CDT
Stocks with insider trader activity include GCAP, HALO and ALIM
HALO: 16.86 (-0.08), ALIM: 4.94 (-0.07), GCAP: 9.81 (-0.06)
Halozyme Therapeutics Reports Selection Of First Product Candidate Under Janssen Collaboration
PR Newswire - Tue Mar 10, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported today that Genmab A/S announced plans for a Phase 1 clinical trial of a subcutaneous formulation of the anti-CD38 antibody daratumumab using the ENHANZE(TM) technology. In December 2014, Janssen Biotech, Inc. (Janssen) entered into an agreement with Halozyme Therapeutics for the purpose of developing and commercializing products combining proprietary Janssen compounds with Halozyme's ENHANZE technology. This agreement has the potential to lead to the development of a subcutaneous formulation of daratumumab. Daratumumab is being developed under a collaboration between Janssen and Genmab A/S since August 2012 when Genmab granted Janssen an exclusive worldwide license to develop, manufacture, and commercialize daratumumab.
HALO: 16.86 (-0.08)
Halozyme Q4 Loss Narrower-than-Expected, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 9:33AM CST
Halozyme (HALO) reports narrower year over year loss in its fourth quarter; Gives 2015 view.
JNJ: 101.08 (+0.62), HALO: 16.86 (-0.08), CBM: 42.97 (+0.37), BAX: 71.14 (-0.37)
Halozyme Therapeutics ups revenues 143% in Q4
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 9:06AM CST
HALO: 16.86 (-0.08)
